Mazdutide (LY3437943) — Dual GLP-1/Glucagon Receptor Agonist

What it is
Mazdutide is an advanced dual GLP-1 and glucagon receptor agonist peptide developed for research into obesity, metabolic disorders, and liver health. Engineered from the glucagon peptide backbone and optimized with fatty acid acylation for once-weekly administration, Mazdutide represents a new generation of metabolic peptides designed to balance appetite regulation and energy expenditure.

How it works (mechanism & pathways)

• GLP-1 receptor activation: Enhances insulin secretion in a glucose-dependent manner, delays gastric emptying, and reduces appetite through central and peripheral satiety pathways.

• Glucagon receptor activation: Increases hepatic lipid oxidation and boosts energy expenditure, promoting a shift toward fat utilization.

The synergistic activation of both receptors produces potent weight reduction, improved insulin sensitivity, and enhanced lipid metabolism, resulting in profound metabolic benefits beyond traditional GLP-1 agonists alone.

Why dual agonism matters
By engaging both GLP-1 and glucagon pathways, Mazdutide stimulates sustained fat burning while preserving lean mass and improving liver function markers. This dual-action mechanism makes it a promising candidate for research into obesity, Type 2 diabetes, and metabolic dysfunction–associated steatohepatitis (MASH).

Key clinical findings (Phase 2)

• Weight reduction: Human trials have shown up to 12–15% mean body-weight loss at higher doses over 48 weeks, comparable to leading incretin therapies.

• Liver and lipid improvements: Studies demonstrate reduced liver fat content, lower triglycerides, and improved ALT/AST levels in subjects with metabolic dysfunction.

• Safety profile: Gastrointestinal side effects (nausea, vomiting) are consistent with the GLP-1 class and generally transient and dose-dependent.

What researchers observe

• Metabolic regulation: Dual receptor engagement supports enhanced energy expenditure and glycemic control.

• Cardiometabolic health: Improved cholesterol and triglyceride levels observed in clinical and preclinical studies.

• Liver support: Early trials indicate reductions in hepatic fat and inflammation, suggesting benefit in MASH models.

Bio Peptide Technologies — Research-ready specs

• Identity: Mazdutide (LY3437943)

• CAS: 2742641-06-1

• Formula / MW: C₂₁₀H₃₂₄N₅₀O₆₆; ~4,548.1 g/mol

• Design: Glucagon-based dual agonist with C20 fatty diacid chain for extended half-life and albumin binding.

Intended use
For research purposes only. Not for human use, medical, or veterinary applications.